MSD Officially Launches Zerbaxa in China to Tackle Drug-Resistant Infections
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced on August 13, 2025, the...
Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 14, 2025,...
Jiangsu Hengrui’s Combo Therapy Approved for Clinical Trials by NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 13, 2025,...
Henlius Biotech’s HLX04-O Accepted by NMPA for Wet AMD Treatment
Shanghai Henlius Biotech Inc. (HKG: 2696) announced on August 13, 2025, that the marketing authorization...
TYK Medicines’ Asandeutertinib Shows Promising Results in Phase II Trial for EGFR-Mutated NSCLC
China-based TYK Medicines, Inc. (HKG: 2410) announced on August 14, 2025, that the results of...
CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma
CANbridge Pharmaceuticals (HKG: 1228) announced on August 13, 2025, that it has entered into a...
Kangji Medical Proposes Privatization, Aiming to Delist from Hong Kong Stock Exchange
Kangji Medical Holdings Limited (HKG: 9997) has submitted a proposal to its shareholders regarding a...
Hengrui Pharmaceuticals Expands Hetrombopag Olamine’s Indication for ITP Patients
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the indication expansion for...
Ascletis Pharma Reports Positive Preclinical Results for ASC47 in Obesity Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) announced encouraging efficacy results from preclinical trials of ASC47,...
Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor
German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August...
Sino Biopharmaceutical’s TQB3142 IND Application Accepted by China’s NMPA for Malignant Tumor Treatment
Sino Biopharmaceutical Limited (HKG: 1177) announced that the Investigational New Drug (IND) application for TQB3142,...
Novartis’ Leqvio Approved by FDA as Standalone Therapy for Hypercholesterolemia
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 12, 2025, that the U.S. Food...
HighTide Therapeutics Collaborates with IMB to Assess HTD1801 in T2DM with CKD
China-based HighTide Therapeutics, Inc. (HKG: 2511) announced the commencement of a collaborative project with the...
FDA Launches PreCheck Program to Strengthen U.S. Pharmaceutical Supply Chain
The U.S. Food and Drug Administration (FDA) announced the launch of “FDA PreCheck” on August...
Pfizer China Restructures Oncology and Rare Disease Units for Enhanced Focus
Pfizer China (NYSE: PFE) announced on August 11, 2025, an organizational optimization of its Oncology and...
China’s NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List
China’s National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025...
Legend Biotech Reports Q2 Revenue Growth of 36.7% and H1 Growth of 60.4%
China-based Legend Biotech Corporation (NASDAQ: LEGN) reported unaudited financial statements for the three months (Q2)...
Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) reported financial results for the first quarter of...
Hengrui’s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China’s NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025,...
Macao Drug Administration Expands White List for Designated Medical Institutions in Cooperation Zone
The Drug Administration of the Macao Special Administrative Region (SAR) of China has announced the...